GBIO
vs
S&P 500
GBIO
S&P 500
Over the past 12 months, GBIO has underperformed S&P 500, delivering a return of -54% compared to the S&P 500's +14% growth.
Stocks Performance
GBIO vs S&P 500
Performance Gap
GBIO vs S&P 500
Performance By Year
GBIO vs S&P 500
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Generation Bio Co
Glance View
Generation Bio Co. is a genetic medicine company focused on creating a new class of gene therapy to provide durable and redosable treatment for patients suffering from both rare and prevalent diseases. The company is headquartered in Cambridge, Massachusetts and currently employs 150 full-time employees. The company went IPO on 2020-06-12. The firm through its non-viral genetic medicine platform, is engaged in developing genetic medicines to provide genetic payloads, which include large and multiple genes to a range of cell types across a range of diseases. The company is comprised of three component technologies: ceDNA, ctLNP and ceDNA manufacturing process. ceDNA is an engineered, double-stranded, linear, covalently closed-ended deoxyribonucleic acid (DNA) construct, which includes the gene of interest and associated regulatory sequences. The company has produced ceDNA constructs of approximately eight kilobases. Its ctLNP delivery system builds upon clinically validated lipid nanoparticles and is designed to allow for repeat dosing of a genetic payload without stimulating an immune response, such as antibody production. Its ceDNA manufacturing process uses its own cell-free rapid enzymatic synthesis (RES) to produce ceDNA.
